Related Experiment Videos
Pneumococcal vaccine development
1R & D Bacterial Vaccine Programme, GlaxoSmithKline Biologicals, Rue de l'Institut, 89 1330 Rixensart, Belgium. jan.poolman@gskbio.com
Expert Review of Vaccines
|October 16, 2004
Summary
Pneumococcal conjugate vaccines significantly reduce bacteremia and pneumonia in children, with herd immunity benefiting adults. Ongoing research aims to improve vaccines for broader protection against pneumococcal diseases.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
- Infectious Diseases
Background:
- Pneumococcal conjugate vaccines (PCVs) have reduced invasive pneumococcal disease in children.
- Herd immunity from childhood vaccination benefits unvaccinated populations.
- Existing polysaccharide vaccines target adults but have limitations for nonbacteremic pneumonia.
Purpose of the Study:
- To review the impact of pneumococcal vaccines on pediatric and adult populations.
- To highlight the development of higher-valency conjugate vaccines.
- To discuss the ongoing need for improved adult pneumococcal vaccines.
Main Methods:
- Review of existing literature and postlicensure data on pneumococcal vaccine efficacy.
- Analysis of epidemiological trends in pneumococcal disease burden.
- Examination of current vaccine development pipelines.
Main Results:
- 7-valent PCV demonstrated significant reductions in pediatric pneumococcal bacteremia and pneumonia.
- Limited but improving impact on pediatric otitis media.
- Established efficacy of 23-valent polysaccharide vaccines against adult bacteremia.
- Persistent high burden of adult nonbacteremic pneumococcal pneumonia.
Conclusions:
- Pneumococcal conjugate vaccines are highly effective in pediatric populations, conferring indirect benefits to adults.
- Development of higher-valency PCVs and novel protein-based vaccines is crucial for addressing adult pneumococcal disease burdens.
- Further research and vaccine innovation are needed to combat pneumococcal pneumonia comprehensively.